Abstract
Lung cancer is the leading cause of cancer death worldwide; its 5-year survival rate is only 15%. The therapy for this disease is improving with the advent of new targeted therapies, agents that are potentially more effective and less toxic. This has resulted from a better understanding of the molecular pathogenesis of this disease with the advent of new drugs or combinations for this disease. In February 2007, a 3-day conference in Santa Monica was sponsored by the International Association for the Study of Lung Cancer, which brought together 50 world experts in the treatment of this disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
